CJC-1295 — GHRH Analog Research Explained

Last updated: May 2026

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). GHRH is a brain-based peptide. It signals the anterior pituitary to produce and release growth hormone (GH). CJC-1295 was engineered to have a longer half-life than native GHRH by resisting enzymatic breakdown. According to a study in the Journal of trial-based Endocrinology. Metabolism (2006), CJC-1295 produced sustained GH. IGF-1 elevations in human subjects at low under-the-skin levels compared to native GHRH.

Next Level Pharm supplies research-grade CJC-1295 (No DAC) tested to at least 99 percent purity by HPLC. Mass spec on every batch. A Certificate of Test with lot number ships with every order for full tracking.

The sections below cover CJC-1295 structure. Its GHRH receptor pathway, half-life research, comparison with the DAC variant. What experts should check before sourcing.

Key Takeaways

What it is: CJC-1295 is a 30-amino-acid GHRH analog designed to boost pituitary GH release with extended duration compared to native GHRH.
Half-life: The No DAC version has a multi-hour half-life in animal models; the DAC version extends this further via albumin binding.
GH axis: Published research links CJC-1295 to increased GH pulse amplitude. IGF-1 levels in both animal and early human studies.
Combined research: CJC-1295 is frequently combined with ipamorelin in study designs examining additive GH axis effects.
Sourcing standard: Research-grade CJC-1295 needs HPLC purity proof, mass spec chain check, and a lot-exact COA.

Here is a closer look at CJC-1295 pathway, published study findings. How it compares to its DAC counterpart.

What Is CJC-1295 and How Was It Developed?

CJC-1295 is a 30-amino-acid synthetic peptide based on the first 29 amino acids of natural GHRH. Plus one more modified residue. experts at ConjuChem developed it by substituting amino acids at positions 2. 8 to resist cleavage by dipeptidyl peptidase IV (DPP-IV), the enzyme. It rapidly degrades native GHRH in circulation.

Native GHRH has a plasma half-life of under 10 minutes in rodent models. CJC-1295 Without Drug Affinity Complex (No DAC) extends this to roughly 30 minutes in lab models by blocking the primary breakdown site. The DAC version adds a reactive ester group that binds circulating albumin to extend duration further. According to a pharmacokinetic study in Growth Hormone. IGF Research (2005), the half-life extension was the primary engineering goal. It differentiated CJC-1295 from earlier GHRH fragment analogs.

How Does CJC-1295 Activate the GHRH Receptor?

CJC-1295 binds the GHRH receptor (GHRHR). A G protein-coupled receptor on somatotroph cells in the anterior pituitary. When GHRHR is triggered, it triggers cyclic adenosine monophosphate (cAMP) signaling inside the cell. This cAMP cascade leads to GH output and pulsatile release into circulation.

The binding affinity of CJC-1295 for GHRHR is similar to native GHRH since the first 29 amino acids responsible for receptor contact are preserved. The changes are placed where DPP-IV binds, not where the receptor binds. This design keeps the receptor trigger intact while extending the window during. Each research level can interact with its target. Downstream IGF-1 output follows from hepatic GH signaling once GH is released.

Browse fitness and GH peptides at Next Level Pharm for COA-tested CJC-1295. Linked GHRH analog research compounds.

What Does Published Research Show for CJC-1295?

According to a study in the Journal of Clinical Endocrinology. Metabolism (2006). A single use of CJC-1295 produced GH elevations lasting several days in healthy adult subjects. The study reported increases in mean 24-hour GH level. IGF-1 levels that persisted longer than any before studied GHRH analog.

Rodent model research published before the human study was confirmed. The modified peptide retained full GHRHR agonist action. GH pulse amplitude increased greatly in a level-dependent pattern across many animal model studies. IGF-1 responses tracked GH changes with expected hepatic lag times of several hours in the study models. These findings established CJC-1295 as a stable GHRH research tool with predictable GH axis drug action.

How Does CJC-1295 No DAC Compare to the DAC Version?

The No DAC version of CJC-1295 has a half-life of roughly 30 minutes in animal models. It produces pulsatile GH release that mimics natural GH release timing. experts use this version when they want to control the timing window of GH boost in their lab protocols.

The DAC version adds a reactive maleimide group that covalently binds circulating albumin after use. Albumin has a half-life of about 19 days, which dramatically extends CJC-1295 DAC duration. This creates a sustained GH rise rather than pulsatile release. According to a comparison analysis in Peptides (2013). The pulse pattern difference is the key variable experts consider when selecting between the two variants for their exact study design.

What Do Combination Studies Show for CJC-1295?

CJC-1295 and ipamorelin trigger different receptor pathways that both converge on pituitary GH release. CJC-1295 acts through GHRHR while ipamorelin acts through the ghrelin receptor (GHS-R1a). When both are present in the same test. The two signals can amplify GH output beyond what either compound produces alone.

Published animal model research shows. GHRH plus a GHS compound produces additive or supra-additive GH responses in rodent models. According to a study in the European Journal of Endocrinology (2000). The combination approach produces a larger. More sustained GH pulse than either alone. This mechanistic rationale explains why experts frequently pair CJC-1295 with ipamorelin in dual-axis study designs examining GH pulse dynamics.

What Quality Standards Apply to Research-Grade CJC-1295?

Research-grade CJC-1295 needs purity above 99 percent confirmed by HPLC before any lab application. HPLC quantifies the peptide peak relative to all other compounds in the sample. A purity reading below this threshold increases the likelihood. Its lab outcomes reflect contaminant action rather than CJC-1295 receptor link alone.

Mass spec confirms that the molecule weight of the batch matches the 30-amino-acid chain exactly. For a modified peptide like CJC-1295, mass spec is mainly key since substitutions at positions 2. 8 change the expected molecule weight from native GHRH. A lot-exact Certificate of Test provides both data points with a reference lot number for tracking if results need to be replicated. Suppliers who test every batch, rather than periodic or sample lots. Provide the most defensible sourcing records for publication. Experts who report findings in peer-reviewed journals are increasingly expected to include supplier name, purity level. Lot number in the materials and methods section of their publications.

Frequently Asked Questions

What is CJC-1295?

CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It was engineered to resist enzymatic breakdown by DPP-IV, extending its half-life compared to native GHRH. Research-grade CJC-1295 is used in lab studies examining pituitary GH release. IGF-1 output in rodent and cell models. The sequence mirrors native GHRH from positions 1 to 29. A modified N-terminus resists DPP-IV cleavage. Studies use it to model sustained GHRH receptor action in pituitary research.

How does CJC-1295 work in research models?

CJC-1295 binds the GHRH receptor (GHRHR) on pituitary somatotroph cells. Receptor trigger triggers a cAMP signaling cascade that boosts GH output and pulsatile release. The modified amino acid chain retains full receptor link affinity while resisting DPP-IV cleavage at the breakdown site. Extending the active research window. The cAMP rise triggers GH vesicle fusion and release. GH enters blood in discrete pulses. This mirrors the normal pulsatile pattern in vivo.

What is the difference between CJC-1295 No DAC and DAC?

CJC-1295 No DAC has a half-life of roughly 30 minutes in animal models. Produces pulsatile GH release. The DAC version adds a maleimide group that binds circulating albumin, extending duration to days. Experts select between the two based on whether their study design needs pulsatile or sustained GH boost patterns. The pulsatile pattern from No DAC mimics natural GHRH rhythm. The DAC form suits longer observation windows in chronic model studies.

What does research show about CJC-1295 and IGF-1?

Published studies report that CJC-1295 use increases mean GH level. IGF-1 levels in animal and human models. IGF-1 rises follow GH rise with expected lag times. A 2006 study in the Journal of trial-based Endocrinology. Metabolism reported sustained IGF-1 increases lasting several days after a single use. The lag reflects IGF-1 output in the liver following GH exposure. That axis is tracked in animal model studies. Experts also measure GH pulse amplitude and frequency.

Why is CJC-1295 combined with ipamorelin in research?

CJC-1295 triggers the GHRH receptor while ipamorelin triggers the ghrelin receptor (GHS-R1a). Both pathways converge on pituitary GH release. When used together in animal models. Published research reports additive or supra-additive GH responses compared to either compound alone. Making the combination useful for dual-axis GH study designs. The two-receptor approach is a common model for GH axis research. Neither compound alone activates both pathways at once. The combination allows separate input levels of each receptor signal.

What purity standard applies to research-grade CJC-1295?

Research-grade CJC-1295 needs HPLC-confirmed purity above 99 percent. Mass spec check of the 30-amino-acid chain molecule weight. Since CJC-1295 has modified residues. It changes its expected mass from native GHRH. Mass spec proof is mainly key for checking the correct structure before lab use. The mass spec check also verifies that DAC modification is present in the DAC version. HPLC confirms the purity percentage. A lot-specific COA links these data to the vial number.

Is CJC-1295 for human use?

The research-grade compound is for lab research only. It is not approved for human use, therapeutic use, or diagnostic purposes. All published research cited in this article used animal models or controlled early-phase study protocols. It should not be given to humans outside of a licensed trial-based trial setting. Research labs order it under standard reagent procurement for in vitro or animal studies. No regulatory body has approved CJC-1295 as a drug or supplement.

Where does CJC-1295 ship from?

Research-grade CJC-1295 ships to all 50 states within the United States. Full lot records including the Certificate of Test ships with every order. HPLC and mass spec data are included for each batch to confirm purity. Chain integrity before lab use. The compound is lyophilized for shipping stability. It arrives as a white powder in a sealed vial. Cold-chain shipping is not required. A lot number links each vial to its COA data for tracking.

Summary

CJC-1295 is a GHRH analog engineered for extended half-life and stable GHRHR trigger. Published research links it to increased GH pulse amplitude. IGF-1 output in animal and early human models. The No DAC variant produces pulsatile GH responses while the DAC variant extends duration via albumin binding. Combined research with ipamorelin shows additive GH axis effects through dual receptor pathway triggers. Research-grade sourcing needs HPLC purity above 99 percent, mass spec chain proof, and a lot-exact COA.

What Should You Do Next?

Browse research-grade CJC-1295 at Next Level Pharm for COA-tested options with lot records. Full HPLC and mass spec data on every batch.

About the Author

Next Level Pharm Research Team

Alex M covers peer-reviewed findings in peptide science for Next Level Pharm, a US-based supplier of research-grade peptides verified to >=99% purity via HPLC and mass spectrometry on every batch.

Disclaimer: The information provided on this page is for educational and research purposes only. Next Level Pharm’s products are intended for laboratory research use only. They are not intended for diagnostic, therapeutic, or medicinal purposes. This content does not constitute medical advice. Always consult a licensed healthcare professional before making any health-related decisions.

CJC-1295 Research: How This GHRH Analog Works in Lab Models